The European Medicines Agency (EMA) is expected today to issue a decision approving the use of the modern coronary vaccine by the US pharmaceutical company Moderna.
The decision was already expected on Monday, but then it had not yet come.
If Moderna's vaccine is authorized by the EMA, it will still have to be authorized by the European Commission.
The first marketing authorization in the EU was obtained during Christmas by an coronary vaccine developed by Pfizer in the United States and Biontech in Germany.
In Finland, vaccinations began on 27 December.
The Pfizer and Biontech vaccine requires a temperature of 70 minus in storage.
Because this is a much lower temperature than conventional freezers, Pfizer and Biontech have been forced to develop special containers for transporting vaccines.
The modern vaccine can instead be stored at 20 minus degrees.
In the United States, the Food and Drug Administration (FDA) approved it for emergency use in the week before Christmas.
Britain, for its part, was the first country in the world to start coronation vaccinations on Monday with a vaccine developed by the Swedish-British pharmaceutical company AstraZeneca and the University of Oxford.
This vaccine is stored in a refrigerator.
It is also much cheaper than competing vaccines.
Last week, Noel Wathion, EMA's deputy director, told the Belgian newspaper Het Nieuwsblad that it was unlikely that the AstraZeneca and Oxford University coroner vaccines would be available in the EU in January.